SUMMARY
Major progress has been made in the treatment of Multiple Myeloma (MM) and new current standard of care has been recently published and includes the introduction of triplet and quadruplet combinations, even in first-line, and the concept of continuous treatment.1 Several new drugs and new associations have been approved and have considerably improved the prognosis of the patients. However, MM remains an incurable disease and patients with high-risk (HR) disease will still experience early relapse. During the European Hematology Association’s annual congress (EHA 2021), results from different trials have highlighted the best options for HR MM, the role of autologous stem cell transplantation, and the exciting results of new anti BCMA-targeting therapy, and have confirmed the results of daratumumab based therapy in first-line treatment.
(BELG J HEMATOL 2021;12(5):220-2)
